A phase I, open label, cohort study of two doses of Cavatak (coxsackievirus type A21) [CVA 21] given intratumourally in stage IV melanoma patients

Trial Profile

A phase I, open label, cohort study of two doses of Cavatak (coxsackievirus type A21) [CVA 21] given intratumourally in stage IV melanoma patients

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs CVA 21 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jan 2010 CVA 21 is adequately tolerated according to results reported in a Viralytics media release.
    • 22 Sep 2009 Status changed from active, no longer recruiting to completed; according to a viralytics media release.
    • 13 Aug 2009 Status changed from recruiting to active, no longer recruiting, according to a Viralytics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top